Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 11, 2024TrialsOpen Access

Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNorbert StefanMHMarek HartlebBPBranko Popović

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Stefan et al. (2024) studied this question.

synapsesocial.com/papers/68e65543b6db6435875e3e27https://doi.org/10.1186/s13063-024-08208-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes2022 · 96 citations
  2. 2Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study2017 · 116 citations
  3. 3A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: <scp>CLDQ</scp>‐<scp>NAFLD</scp>2017 · 104 citations
  4. 4Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia2020 · 53 citations
  5. 5Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease2018 · 387 citations